Clinical trials
Schizophrenia trials in Hungary
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
53 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2003 | 2 |
| 2004 | 5 |
| 2005 | 2 |
| 2006 | 1 |
| 2007 | 4 |
| 2008 | 4 |
| 2010 | 6 |
| 2011 | 3 |
| 2012 | 2 |
| 2013 | 2 |
| 2014 | 1 |
| 2015 | 1 |
| 2016 | 3 |
| 2017 | 4 |
| 2018 | 2 |
| 2019 | 1 |
| 2020 | 1 |
| 2021 | 2 |
| 2022 | 4 |
| 2025 | 1 |
| 2026 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 41 |
| Terminated | 9 |
| Recruiting | 2 |
| Not yet recruiting | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 9 |
| AstraZeneca | 6 |
| Janssen-Cilag International NV | 5 |
| ACADIA Pharmaceuticals Inc. | 4 |
| Hoffmann-La Roche | 3 |
| AbbVie | 2 |
| Boehringer Ingelheim | 2 |
| H. Lundbeck A/S | 2 |
| Janssen Research & Development, LLC | 2 |
| Solvay Pharmaceuticals | 2 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Schizophrenia | 53 |
| Psychotic Disorders | 4 |
| Mental Disorders | 3 |
| Autistic Disorder | 2 |
| Cognitive Dysfunction | 2 |
| Schizophrenia Spectrum and Other Psychotic Disorders | 2 |
| Bipolar Disorder | 1 |
| Body Weight Changes | 1 |
| Mania | 1 |
| Metabolic Syndrome | 1 |
Trials
Showing 51 to 53 of 53. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.